Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years 2. Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes: Polycythemia Vera (PV) Criteria: * Elevated hemoglobin (\>16.5 g/dL for men, \>16.0 g/dL for women), hematocrit (\>49% for men, \>48% for women), or increased red cell mass * Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis) * Presence of JAK2 mutation (V617F or exon 12) Essential Thrombocythemia (ET) Criteria: * Platelet count ≥450 ×10⁹/L * Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage * Not meeting WHO criteria (Alaggio et al., 2022) for other myeloid neoplasms (such as CML, PV, PMF, MDS). * Presence of JAK2, CALR, or MPL mutation Primary Myelofibrosis (PMF) Criteria * Megakaryocytic proliferation and atypia, with or without reticulin fibrosis, and increased marrow cellularity (for prefibrotic/early PMF) or significant reticulin/collagen fibrosis (for overt PMF) * Not meeting criteria for other myeloid neoplasms * Presence of JAK2, CALR, or MPL mutation, or in their absence, another clonal marker 3. Patients who are referred for a bone marrow biopsy due to a suspected diagnosis of MPN Exclusion Criteria: 1. Patients diagnosed with MPN receiving therapy 2. Patients who have undergone a bone marrow transplant